Gsa Capital Partners LLP Passage Bio, Inc. Transaction History

Gsa Capital Partners LLP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$0.96 - $1.88 $22,417 - $43,901	23,352 Added 21.86%	130,188 $124,000
Q4 2022 Feb 13, 2023	BUY	$1.06 - $1.48 $22,938 - $32,027	21,640 Added 25.4%	106,836 $147,000
Q3 2022 Nov 14, 2022	SELL	$1.22 - $2.48 $5,499 - $11,179	-4,508 Reduced 5.03%	85,196 $106,000
Q2 2022 Aug 09, 2022	BUY	$1.63 - $3.46 $35,313 - $74,960	21,665 Added 31.84%	89,704 $212,000
Q1 2022 May 11, 2022	BUY	$2.66 - $6.49 $119,574 - $291,744	44,953 Added 194.72%	68,039 $211,000
Q4 2021 Feb 14, 2022	BUY	$6.24 - $10.2 $6,907 - $11,291	1,107 Added 5.04%	23,086 $147,000
Q3 2021 Nov 12, 2021	BUY	$9.73 - $15.52 $213,855 - $341,114	21,979 New	21,979 $219,000

38.7M

7.7K

Ticker PASG
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,463,200
Market Cap $32.1M
Description
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 ...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.